Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Provided By GlobeNewswire
Last update: Nov 5, 2024
Turnstone’s next-generation Selected TIL technology is designed to selectively expand the most potent tumor-reactive T cells for treatment of solid tumors
Results further support the continued clinical advancement of TIDAL-01, currently being evaluated in Phase 1 trials
Read more at globenewswire.comNASDAQ:TSBX (6/9/2025, 8:00:01 PM)
0.3659
+0 (+1.36%)
Find more stocks in the Stock Screener
TSBX Latest News and Analysis
6 days ago - ChartmillWhich stocks have an unusual volume on Wednesday?Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume.
